NO20060871L - Azepinderivater som farmasoytiske midler - Google Patents

Azepinderivater som farmasoytiske midler

Info

Publication number
NO20060871L
NO20060871L NO20060871A NO20060871A NO20060871L NO 20060871 L NO20060871 L NO 20060871L NO 20060871 A NO20060871 A NO 20060871A NO 20060871 A NO20060871 A NO 20060871A NO 20060871 L NO20060871 L NO 20060871L
Authority
NO
Norway
Prior art keywords
pharmaceutical agents
azepine derivatives
receptors
activity
azepine
Prior art date
Application number
NO20060871A
Other languages
English (en)
Inventor
Richard Martin
Tie-Lin Wang
Brenton Flatt
Xiao-Hui Gu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of NO20060871L publication Critical patent/NO20060871L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er frembrakt forbindelser, preparater og fremgangsmåter for å modulere reseptorers aktivitet og for behandling, forebyggelse eller lindring av et eller flere symptomer på sykdom eller forstyrrelse som henger sammen med reseptorers aktivitet.
NO20060871A 2003-07-23 2006-02-22 Azepinderivater som farmasoytiske midler NO20060871L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
PCT/US2004/023745 WO2005009387A2 (en) 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
NO20060871L true NO20060871L (no) 2006-04-24

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060871A NO20060871L (no) 2003-07-23 2006-02-22 Azepinderivater som farmasoytiske midler

Country Status (14)

Country Link
US (1) US8466143B2 (no)
EP (1) EP1648408A4 (no)
JP (1) JP4679517B2 (no)
KR (1) KR20060052867A (no)
CN (1) CN1852748A (no)
AU (1) AU2004259009A1 (no)
BR (1) BRPI0412262A (no)
CA (1) CA2532798C (no)
CR (1) CR8258A (no)
EC (1) ECSP066392A (no)
IL (1) IL173287A0 (no)
NO (1) NO20060871L (no)
RU (1) RU2006105646A (no)
WO (1) WO2005009387A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
DE602004019118D1 (de) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
EA200701984A1 (ru) 2005-03-14 2008-02-28 Глэксо Груп Лимитед Конденсированные тиазольные производные, обладающие сродством к гистаминовому h3 рецептору
RU2008128823A (ru) * 2005-12-15 2010-01-20 Экселиксис, Инк. (Us) Производные азепиноиндола в качестве фармацевтических средств
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
TWI482773B (zh) * 2008-10-31 2015-05-01 Medivation Technologies Inc 氮呯并〔４，５－ｂ〕吲哚及使用方法
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
BRPI1010604A2 (pt) * 2009-05-22 2017-05-23 Abbott Gmbh & Co Kg moduladores dos receptores 5-ht e métodos de uso dos mesmos
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
RU2567751C2 (ru) 2010-05-21 2015-11-10 Эббви Инк. Трициклические производные пирролидина, полезные в качестве модуляторов 5-ht рецепторов
WO2012154261A1 (en) 2011-02-18 2012-11-15 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US20140303144A1 (en) * 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
WO2014031165A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
SG10202010386PA (en) * 2014-11-21 2020-11-27 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
SG11201704770YA (en) * 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3274350A1 (en) * 2015-03-26 2018-01-31 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
WO2017205684A1 (en) * 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
SG10202011665SA (en) * 2016-05-25 2020-12-30 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
EP3743417A1 (en) * 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
CA2297988A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
BR0011696A (pt) 1999-06-18 2002-04-30 Cv Therapeutics Inc Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
RU2008128823A (ru) * 2005-12-15 2010-01-20 Экселиксис, Инк. (Us) Производные азепиноиндола в качестве фармацевтических средств

Also Published As

Publication number Publication date
CA2532798C (en) 2013-02-19
BRPI0412262A (pt) 2006-09-19
AU2004259009A1 (en) 2005-02-03
CR8258A (es) 2006-08-30
US8466143B2 (en) 2013-06-18
JP4679517B2 (ja) 2011-04-27
CN1852748A (zh) 2006-10-25
EP1648408A1 (en) 2006-04-26
US20070015746A1 (en) 2007-01-18
KR20060052867A (ko) 2006-05-19
WO2005009387A3 (en) 2006-03-02
EP1648408A4 (en) 2006-11-29
WO2005009387A2 (en) 2005-02-03
ECSP066392A (no) 2007-01-26
JP2006528637A (ja) 2006-12-21
IL173287A0 (en) 2006-06-11
RU2006105646A (ru) 2007-09-10
CA2532798A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20060871L (no) Azepinderivater som farmasoytiske midler
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
BR0313562A (pt) derivados de indol ou benzimidazol para a modulação da ikb-cinase
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
MY145074A (en) Thiazolidin-4-one derivatives
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
ATE453628T1 (de) Nucleosidderivate und deren therapeutische verwendung
NO20051013L (no) N-ureidoalkyl-piperidiner som modulerende forbindelser av kjemokinreseptor-aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application